定增预案显示，此次发行的定价基准日为第十一届董事会第十五次（临时）会议决议公告日（2026年2 月12日），发行价格为6.32元/股，不低于定价基准日前20个交易日公司股票交易均价的80%，发行对象 只有一个，即控股股东长江产业集团。 从募资用途来看，6亿元资金将直接用于偿还借款和补充流动资金。广济药业在预案中坦言，此举旨在 优化资本结构，提高抗风险能力。 近期，广济药业（000952.SZ）的一纸公告，将这家老牌维生素生产商推至聚光灯下。 公司发布的《2026年度向特定对象发行A股股票预案》显示，拟向控股股东长江产业投资集团有限公司 （以下简称"长江产业集团"）定向发行不超过9493.67万股，募集资金总额不超过6亿元，扣除发行费用 后将全部用于偿还借款和补充流动资金。 在这场看似常规的再融资操作背后，是广济药业难以掩盖的经营窘境：连续三年巨额亏损、资产负债率 攀升至历史高位、核心产品价格长期低迷。这家曾经的维生素B2龙头，究竟陷入了怎样的困局？6亿元 资金能否成为解困的"灵丹妙药"。 针对此次定增的具体安排以及公司经营方面的问题，《中国经营报》记者日前向广济药业方面致函采 访，公司证券部工作人员表示，会将 ...

（文章来源：新京报） 新京报讯（记者刘旭）2月11日，湖北广济药业股份有限公司（简称"广济药业"）发布2026年向特定对 象发行A股股票预案，公司拟向控股股东长江产业集团发行股票募资不超过6亿元，扣除发行费用后将 全部用于偿还借款及补充流动资金。本次发行价格为6.32元/股。 广济药业表示，截至2025年9月30日，公司的资产负债率为62.67%，公司目前较高的资产负债率加大了 公司债务融资的成本，本次发行有利于公司优化资本结构，提高抗风险能力。同时，有利于稳固公司股 权结构，提升公司控制权稳定性；也有利于向社会公众传递积极信息，提升公司投资价值。 2025年10月以来，广济药业董事会曾四次审议通过向银行申请综合授信额度的议案，目的均为实现业务 发展和正常经营所需，包括：向中国民生银行股份有限公司武汉分行申请综合授信1.5亿元，授信期限1 年（其中中长期流动资金贷款支用额度不超过1亿元，期限不超过2年），担保方式为抵押，年利率不超 过3%；向华夏银行黄冈分行申请1.25亿元综合授信，其中1亿元可用于短期流动资金贷款，年利率不超 过2.98%，或开具1.25亿元银行承兑汇票，无抵押担保，资金用途包括采购原材料、 ...

Core Viewpoint - Hubei Guangji Pharmaceutical Co., Ltd. plans to issue up to 94,936,708 A-shares to its controlling shareholder, Changjiang Industrial Investment Group, raising a total of no more than 600 million yuan, which will improve the company's financial status and enhance its resilience against macroeconomic fluctuations [1][3] Group 1: Fundraising and Shareholding Structure - The fundraising will be used to repay loans and supplement working capital, which is expected to improve the company's financial condition [3][5] - After the issuance, Changjiang Industrial Group's shareholding will significantly increase, demonstrating the controlling shareholder's confidence in the company's long-term development [1][3] Group 2: Strategic Positioning and Industry Context - Changjiang Industrial Group is the only provincial-level industrial investment platform in Hubei, focusing on strategic emerging industries, including biomedicine [3][4] - The company aligns with Hubei's "14th Five-Year Plan," which emphasizes the development of high-end medical devices and biomedicine as key growth areas [4] Group 3: Business Structure and Competitive Advantages - Guangji Pharmaceutical is a major global supplier of Vitamin B2, with a market share of approximately 30%, and has a strong operational efficiency and cost control [5][7] - The company has a long history of technological accumulation in Vitamin B2 production, maintaining stable customer relationships and a robust supply chain [7][9] Group 4: Market Trends and Future Outlook - The Vitamin B2 market is entering a down cycle but is expected to recover as global feed demand increases and synthetic biology technology reshapes cost structures [9] - The 600 million yuan fundraising is seen as the beginning of a transformation from a traditional manufacturer to a health platform enterprise [9]

Core Viewpoint - Guangji Pharmaceutical (000952) plans to raise up to 600 million yuan through a private placement to its controlling shareholder, Changjiang Industrial Group, at a price of 6.32 yuan per share, aimed at optimizing its capital structure and addressing financial pressures [1] Group 1: Fundraising and Financial Strategy - The funds raised will be used to repay loans and supplement working capital, with the company's debt-to-asset ratio standing at 62.67% as of September 30, 2025 [1] - The controlling shareholder's stake will increase from 25.26% to 41.33%, indicating strong support for the company [1] Group 2: Performance Forecast - The company anticipates a net loss of between 399 million yuan and 518 million yuan for 2025, marking the third consecutive year of losses, following losses of 140 million yuan in 2023 and 295 million yuan in 2024 [1] - Revenue has declined for two consecutive years, with 2024 revenue reported at 639 million yuan, a year-on-year decrease of 13.42% [3] Group 3: Recent Developments - On February 13, 2026, the company announced the receipt of a drug registration certificate for Mecobalamin tablets, which are used for the treatment of peripheral neuropathy [1] - The company also faces potential shareholder compensation risks due to possible information disclosure issues [1] Group 4: Market Performance - Over the past week (February 9 to 13, 2026), Guangji Pharmaceutical's stock price has shown a slight upward trend, with a price increase of 1.64% and a trading range fluctuation of 5.29% [2] - On February 13, the stock closed at 8.07 yuan, up 1.51%, with a trading volume of 94.31 million yuan and a turnover rate of 3.35% [2] - Technical indicators suggest a weak bullish signal, with the stock touching the upper Bollinger Band at 8.33 yuan [2] Group 5: Institutional Insights - Overall institutional ratings are neutral, with no significant bullish or bearish views [4] - The fund holding ratio is only 0.04%, indicating low institutional interest and activity [4] - Market attention remains moderate, with no clear directional guidance from public sentiment regarding short-term events [4]

Group 1 - Hubei Guangji Pharmaceutical Co., Ltd. plans to issue up to 94,936,708 A-shares to its controlling shareholder, Yangtze Industry Investment Group, raising a total of no more than 600 million RMB [1] - The purpose of the private placement is to repay company loans and supplement working capital, aiming to optimize capital structure and enhance financial stability [1] - As of September 2025, Guangji Pharmaceutical's debt-to-asset ratio is 62.67%, and the company has experienced continuous losses since 2023, with a projected net loss of between 399 million RMB and 518 million RMB for 2025 [1] Group 2 - The main reasons for the losses include long-term low prices in the vitamin B2 market and intense market competition, which have prevented sales prices from recovering [1] - The company believes that the private placement will enhance its risk resistance and reflects the controlling shareholder's confidence in the company's future development, which is beneficial for consolidating control [1] - The vitamin B2 market is expected to enter a phase of moderate growth starting in 2026 due to adjustments in market demand and opportunities for cost reduction from technological upgrades [1]

长江产业集团将现金全额认购，所购股份36个月内不得转让。资金主要用于偿还借款和补充流动资金， 以优化资本结构，降低资产负债率。截至2025年9月30日，公司资产负债率为62.67%，较高的负债率增 加了债务融资成本。此次定增有助于缓解资金压力，增强抗风险能力与盈利能力。 广济药业主营维生 素B2、B6及医药制剂产品，是全球主要的维生素B2供应商之一。近年来，受市场竞争加剧影响，主要 产品销售价格长期低位，导致业绩持续亏损。财报显示，2023年至2025年，公司净利润连续三年亏损， 且亏损金额持续增长。此外，产线开工率不足、产品市场价格下行等因素也对公司业绩造成不利影响。 据经济观察报-经济观察网 2月11日，广济药业（000952.SZ）公告拟向控股股东长江产业投资集团有限 公司定增募资。 本次发行股票数量不超过94,936,708股，价格为6.32元/股，募集资金总额不超过6亿 元。 市场研究机构预计，2026年开始维生素B2或进入温和增长期。对于广济药业而言，能否依靠控股股东 的驰援扛过周期底部，仍待进一步观察。 ...

Core Viewpoint - Guangji Pharmaceutical (000952.SZ) has proposed a private placement plan to raise up to 600 million yuan, seeking support from its controlling shareholder, Changjiang Industrial Investment Group, amid a projected loss of 399 million to 518 million yuan for 2025 [1][5]. Group 1: Private Placement Details - The private placement will involve a cash subscription by Changjiang Industrial Group, which holds 25.26% of Guangji Pharmaceutical's shares [2]. - The issuance price is set at 6.32 yuan per share, not lower than 80% of the average trading price over the previous 20 trading days [2]. - The number of shares to be issued will not exceed 94,936,708, representing up to 30% of the company's total shares prior to the issuance [2]. Group 2: Company Background and Market Context - Guangji Pharmaceutical specializes in Vitamin B2, B6, and pharmaceutical formulations, being a major global supplier of Vitamin B2, with applications in pharmaceuticals, feed additives, and food additives [3]. - The company has faced continuous net profit losses for three years, with losses increasing from 140 million yuan in 2023 to an expected 399 million to 518 million yuan in 2025, primarily due to low market prices for Vitamin B2 [5][6]. - The demand for vitamins is expected to rise due to improving living standards and health awareness, supported by government policies promoting high-quality vitamin production [3]. Group 3: Financial Health and Future Outlook - As of September 30, 2025, the company's debt-to-asset ratio was 62.67%, indicating high debt financing costs [4]. - The company has been experiencing operational losses due to low production line utilization and declining product prices, leading to asset impairment [6][7]. - Market analysts predict a mild growth phase for Vitamin B2 starting in 2026, with potential stabilization of prices and improved production efficiency due to technological upgrades [7].

广济药业主营维生素B2、B6及医药制剂产品，广泛应用于医药原料药、饲料添加剂和食品添加剂等领 域。公司旗下拥有武穴、孟州等四个生产基地，主导产品包括不同等级的核黄素及其衍生物，以及口服 固体制剂和大输液类产品。 经观健康 广济药业（000952）(000952.SZ)近期公布了一项总额不超过6亿元的定向增发方案，旨在从其控股股东 长江产业投资集团获取资金支持。作为全球维生素B2的主要供应商之一，广济药业近期发布2025年业 绩预告，预计全年将出现3.99亿元至5.18亿元的亏损。 根据广济药业发布的《2026年向特定对象发行A股股票预案》，此次定增的发行对象为湖北省国资旗下 的长江产业集团，该集团目前持有公司25.26%的股份，是其主要股东。本次定增定价基准日为第十一 届董事会第十五次(临时)会议决议公告日，发行价格为6.32元/股，不低于前20个交易日股票均价的 80%。拟发行股份数量上限为94,936,708股，不超过公司总股本的30%，最终数量将在通过深交所审核 并获得证监会注册后由公司董事会与保荐机构协商确定。 自2023年以来，由于维生素B2市场价格持续低迷，广济药业已连续三年出现净利润亏损，且亏损 ...

Group 1 - The article discusses the impact of winter conditions on skin dryness and suggests dietary solutions to alleviate this issue [1][2] - Foods rich in Vitamin A, such as liver, fatty fish, carrots, and spinach, are recommended to combat skin dryness and improve skin texture [1] - Vitamin B2 is essential for preventing skin conditions like cheilitis and seborrheic dermatitis, found in dairy, eggs, meats, and various vegetables [1] - Vitamin C-rich foods, including jujubes, bell peppers, and kiwis, are highlighted for their role in collagen synthesis and skin health [1] - Foods containing fructose, such as grapes and bananas, can help retain moisture in the body [1] Group 2 - The article emphasizes the importance of consuming quality fats for maintaining smooth skin, recommending nuts and seeds like walnuts and sesame paste [2] - It cautions against overconsumption of these foods to avoid weight gain [2]

业绩方面，2025年1月-9月，广济药业实现营业收入4.29亿元，同比减少7.12%；归属净利润-9729.86万 元，同比增长38.64%。 异动原因 来源：市场资讯 涉及维生素B2概念，为全球主要维生素B2产品供应商；涉及流感概念，其生产的小儿氨酚黄那敏颗粒 可缓解儿童普通感冒及流行性感冒引发的发热、头痛等相关症状；具有国企背景，控股股东为长江产业 投资集团，最终控制人为湖北省国资委。 11月24日，广济药业收盘首板涨停，沪深京交易所数据显示，截至当日收盘，广济药业报7.83元/股，成 交额5081.14万元，总市值27.15亿元，封板资金3001.8万元。 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 ...